Subtype
Head and Neck Squamous Cell Carcinoma
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
592 active trials6 approved drugs53 evidence items
- NCIt
- C34447
- OncoTree
- HNSC
- DOID
- 5520
- UMLS CUI
- C1168401
- MeSH
- D000077195
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02454179 | Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma(KEYNOTE147) | completed | Phase 2 | 78 | Acerta Pharma BVINDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01581970 | Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer | completed | Phase 2 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 11, 2019 |
| clinicaltrials |
| NCT02715596 | Changes in Body Composition After EPA Supplementation in Head and Neck Patients(hepaneck) | completed | Phase 3 | 54 | Institut Català d'OncologiaOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT03575234 | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02765503 | Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial(HYPNO) | unknown | N/A | 836 | International Atomic Energy AgencyOTHER_GOV | 9 | Aug 8, 2019 | clinicaltrials |
| NCT03611205 | Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Aug 7, 2019 | clinicaltrials |
| NCT02473731 | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients | completed | Phase 1 | 12 | Celldex TherapeuticsINDUSTRY | 1 | Aug 1, 2019 | clinicaltrials |
| NCT03830385 | Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck | unknown | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT03998696 | An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.(HNC) | completed | Phase 4 | 60 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT00894413 | A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract | completed | Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT00442455 | Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck | completed | Phase 3 | 53 | Grupo de Investigación Clínica en Oncología RadioterapiaOTHER | 1 | Jun 6, 2019 | clinicaltrials |
| NCT01064921 | Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma | completed | Phase 1 | 27 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03926468 | Liquid Biopsy in Head and Neck Cancer | unknown | — | 30 | Turku University HospitalOTHER_GOV | 1 | Jun 4, 2019 | clinicaltrials |
| NCT02663583 | Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell | unknown | — | 44 | M.D. Anderson Cancer CenterOTHER | 1 | May 23, 2019 | clinicaltrials |
| NCT02069158 | Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor(IOSI-NDU-001) | completed | Phase 1 | 17 | Cristiana SessaOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT03938012 | Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma | unknown | — | 80 | National University Hospital, SingaporeOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03917537 | WGA in Platinum-refractory HNSCC Underwent Nivolumab | unknown | — | 80 | Chang Gung Memorial HospitalOTHER | 1 | Apr 25, 2019 | clinicaltrials |
| NCT03923998 | Adjuvant ChemoRadiotherapy Prior to Surgery in Stage IVa Oral Cancers | completed | Early Phase 1 | 8 | Indrayani Hospital and Cancer InstituteOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03325465 | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT02277197 | Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | completed | Phase 1 | 14 | James J LeeOTHER | 1 | Apr 18, 2019 | clinicaltrials |
| NCT03917524 | Feasibility of CTCs Isolation for Transcriptomes and Genome Wide Associated Analysis in Post-OP High Risk OSCC Patients.(CTC) | unknown | — | 180 | Chang Gung Memorial HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT01716416 | Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)(HNSCC) | completed | Phase 1 | 32 | Washington University School of MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | terminated | Phase 2 | 1 | University of ChicagoOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)(PICH) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Antoine LacassagneOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02565758 | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors | completed | Phase 1 | 85 | AbbVieINDUSTRY | 3 | Apr 5, 2019 | clinicaltrials |
| NCT03160495 | Functional ImaGing of Heterogeneity in Head and Neck Tumors - Validation From Surgical Specimens(FIGHHT) | completed | — | 33 | Rigshospitalet, DenmarkOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT02216916 | Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy | unknown | Phase 2 | 49 | Yonsei UniversityOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT02508246 | WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 | 12 | University of WashingtonOTHER | 1 | Mar 13, 2019 | clinicaltrials |
| NCT03226613 | New Modalities for Detection of Oropharyngeal Cancer | completed | N/A | 51 | Vanderbilt University Medical CenterOTHER | 1 | Mar 13, 2019 | clinicaltrials |
| NCT02347332 | Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer | completed | Phase 3 | 459 | Pierre Fabre MedicamentINDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT03179956 | Impact of Ribociclib on Head and Neck Squamous Cell Cancer | terminated | Early Phase 1 | 1 | Fox Chase Cancer CenterOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT03843671 | Hyperbaric Radiation Sensitization of Head and Neck Cancers | unknown | Phase 2 | 400 | National Baromedical ServicesOTHER | 2 | Feb 18, 2019 | clinicaltrials |
| NCT03121313 | Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+ | unknown | Phase 2 | 68 | Chang Gung Memorial HospitalOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies(COTI2-101) | unknown | Phase 1 | 51 | Critical Outcome Technologies Inc.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03619304 | Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line | unknown | N/A | 20 | Cairo UniversityOTHER | 0 | Jan 30, 2019 | clinicaltrials |
| NCT02388932 | Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer | terminated | N/A | 3 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT02205398 | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | terminated | Phase 1 | 13 | Novartis PharmaceuticalsINDUSTRY | 7 | Jan 22, 2019 | clinicaltrials |
| NCT01233843 | Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.(2007/02) | completed | Phase 3 | 370 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT01696955 | Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery | completed | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03246685 | Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD | terminated | Phase 2 | 1 | HiberCell, Inc.INDUSTRY | 1 | Dec 14, 2018 | clinicaltrials |
| NCT02035735 | Interest of Narrow Band Imaging in Detection of Upper Aerodigestive Cancers | completed | N/A | 93 | University Hospital, ToulouseOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT03744208 | SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 30 | Shi YuankaiUNKNOWN | 0 | Nov 16, 2018 | clinicaltrials |
| NCT03727594 | Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma | unknown | — | 50 | University Hospital of FerraraOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT03529604 | Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients(OCSALTM) | unknown | — | 100 | University of ZagrebOTHER | 0 | Oct 16, 2018 | clinicaltrials |
| NCT03053661 | Immune Response Evaluation to Curative Conventional Therapy(IRECT-01) | unknown | — | 22 | University of UlmOTHER | 0 | Oct 11, 2018 | clinicaltrials |
| NCT03096184 | A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers | unknown | Phase 2 | 38 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00055913 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01941992 | Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients(ROSAM) | completed | Phase 2 | 120 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 13, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Sep 12, 2019source: clinicaltrials